Physician profile
Natalie Basin
NPI 1477196897
$3,141.85
in general payments reported to CMS, 2019-2025
22 companies · $966 in 2025
The $966 reported for 2025 was more than what 80% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $254 · 2022: $803 · 2023: $869 · 2024: $250 · 2025: $966.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,885 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,884.96 |
| Education | $199.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $388.55 | 2021-2025 | Winlevi, Absorica Ld |
| Abbvie INC. | $349.64 | 2023-2025 | |
| Pfizer INC. | $251.94 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $244.65 | 2022-2023 | Sotyktu |
| Amgen INC. | $235.28 | 2023-2025 | Otezla, Otezla |
| Allergan, INC. | $216.22 | 2022 | |
| Incyte Corporation | $198.77 | 2021-2023 | Opzelura |
| Janssen Biotech, INC. | $184.60 | 2025 | Tremfya |
| Genzyme Corporation | $170.03 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $164.96 | 2023-2025 | Dupixent, Libtayo |
| Almirall LLC | $121.28 | 2021-2023 | Klisyri |
| Lilly USA, LLC | $114.19 | 2023-2025 | Ebglyss, Taltz, Mounjaro |
| Sanofi-Aventis U.S. LLC | $99.99 | 2025 | |
| Arcutis Biotherapeutics, INC. | $98.77 | 2023-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $97.27 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $69.78 | 2022-2025 | Nemluvio |
| Merz North America, INC. | $31.92 | 2022 | |
| Leo Pharma INC. | $27.62 | 2023 | Adbry |
| Ucb, INC. | $27.48 | 2025 | Bimzelx |
| Octapharma USA, INC. | $17.34 | 2024 | Octagam Immune Globulin (Human) |
| Lnhc, INC | $15.98 | 2025 | Zelsuvmi |
| Vyne Pharmaceuticals INC. | $15.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Basin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.